Targeted Treatments for Haematological Cancers

Friday 21 June, 2019 Royal Marsden Hospital, London

Level: Intermediate/Advanced –  Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.

Description:  In this study day I describe the unique cellular and genetic features of haematological cancers and covers a diverse range of targeted treatments for leukaemias, lymphomas and multiple myeloma. Treatments explained include a wide range of monoclonal antibodies, B cell receptor signalling blockers and JAK2, Bcl-2, FLT3 and CDK inhibitors. I also explore the potential of immunotherapy with checkpoint inhibitors and CAR T cells.

To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922

 

Topics

Key molecular concepts in leukaemia, lymphoma and myeloma
  • Unique properties of myeloid and lymphoid cells
  • Types of DNA damage and common chromosome translocations and their consequences
  • Key genetic mutations & molecular pathways
Monoclonal antibodies against CD antigens
  • Different types of mAb treatments: naked, conjugated, direct-acting, indirect-acting, bi-specific
  • Anti-CD20 antibodies e.g. rituximab, ofatumumab, veltuzumab, obinutuzumab
  • More mAbs e.g., brentuximab vedotin, blinatumomab, alemtuzumab, inotuzumab ozogamicin, gemtuzumab ozogamacin
Faulty signalling pathways and how to target them
  • Receptor Tyrosine Kinases (RTKs) such as FLT3 and KIT
  • JAK2 inhibitors e.g. ruxolitinib
  • The B-cell receptor – inhibitors of PI3K (e.g. ibrutinib) and PI3Kdelta (e.g. idelalisib)
Targeting the cell cycle and cell survival
  • Targeting the cell cycle with CDK inhibitors
  • Targeting cell survival with Bcl-2 inhibitors
Specific treatment for individual cancers
  • Acute leukaemias: PML/RARα (ATRA and arsenic trioxide); CAR T-cell therapy
  • Chronic Myeloid Leukaemia: Bcr-Abl inhibitors (imatinib, dasatinib, nilotinib, ponatinib)
  • Hodgkin lymphoma: PD-1 antibodies
  • Myeloma: proteasome inhibitors (bortezomib, carfilzomib, ixazomib), thalidomide & lenalidomide, monoclonal antibodies (elotuzumab, daratumumab)